参麦注射液联合化疗对晚期非小细胞肺癌患者T细胞亚群及细胞因子的影响

王蓉; 李大鹏; 冯军

参麦注射液联合化疗对晚期非小细胞肺癌患者T细胞亚群及细胞因子的影响

苏州大学附属第一医院，江苏苏州 215006

计量
- 文章访问数: 606
- HTML全文浏览量: 3
- PDF下载量: 630
- 被引次数: 0
出版历程
- 收稿日期: 2015-09-27
- 修回日期: 2015-11-14
- 刊出日期: 2016-03-10

The Influence of Shenmai Injection Combined with Chemotherapy on T cell Subgroups and Cytokines of Advanced Non-small Cell Lung Cancer Patients

摘要

摘要: 目的研究参麦注射液联合化疗对晚期非小细胞肺癌（NSCLC）患者的T细胞亚群及细胞因子表达的影响。方法将符合研究标准的48例患者随机分为联合治疗组和单纯化疗组，鳞癌患者均予多西紫杉醇联合顺铂化疗、腺癌及大细胞癌均予培美曲塞二钠联合顺铂化疗，联合治疗组在上述方案上加用参麦注射液。在化疗前及化疗2周期后检测外周T淋巴细胞亚群及NK细胞活性等免疫指标，检测外周血细胞因子水平，同时评价患者化疗近期疗效及不良反应。结果治疗后联合治疗组CD4⁺水平及CD4⁺/CD8⁺明显升高(P<0.05~0.01)，与单纯化疗组比，CD3⁺、CD4⁺水平及CD4⁺/CD8⁺有显著性差异（P<0.01）。联合治疗组IFN-γ、TNF-α、IL-2、IL-6含量明显升高（P<0.01），与单纯化疗组比，IFN-γ、IL-2有显著性差异（P<0.01）。2组近期疗效无统计学差异。联合治疗组中血液学毒性发生率较单纯化疗组下降（P<0.05~0.01）。结论参麦注射液联合化疗能改善晚期非小细胞肺癌患者的细胞免疫功能，进一步逆转Th1向Th2漂移。
- 参麦注射液 /
- 非小细胞肺癌 /
- 化疗 /
- 免疫功能 /
- 细胞因子
Abstract: OBJECTIVE To observe the impact of Shenmai injection combined with chemotherapy on advanced non-small cell lung cancer patients' immunity and cytokines. METHODS 48 cases were randomly divided into two groups: the combining treatment group and the chemotherapy group. Patients with squamous carcinoma were given Docetaxel and cisplatin chemotherapy; patients with adenocarcinomas and large cell carcinoma were given pemetrexed disodium together with cisplatin chemotherapy. Shenmai injection was added in the combining treatment group. Immune indexes like peripheral T lymphocyte subsets and the viability of NK cells together with peripheral blood cell factor level and short term effects of chemotherapy and the side effects shown were recorded before the chemotherapy and two cycles of treatment. RESULTS After treatment，the level of CD4⁺ and CD4⁺/CD8⁺ in combined treatment group increased significantly(P<0.05~0.01). Compared to the chemotherapy group， the levels of CD3⁺， CD4⁺ and CD4⁺/CD8⁺ of treatment group have significant difference(P<0.01). The expression of IFN-γ， TNF-α， IL-2 in combination group increased significantly(P<0.01). The levels of IFN-γ and IL-2 of treatment group had significant difference(P<0.01) ，compared with the control group. The response rate of these two groups is similar.The incidence of hematologic toxicities in the treatment group was lower than that in control group(P<0.05~0.01). CONCLUSION The combination of Shenmai injection with chemotherapy can improve advanced stage non-small lung cancer patients' immunity and reverse the Th1/Th2 ratio， and reduce the toxicity of chemotherapy.
- Shenmai injection /
- non-small cell lung cancer /
- chemotherapy /
- immunity /
- cytokines

HTML全文

参考文献(20)

[1]	孙燕.内科肿瘤学[M].北京：人民卫生出版社，2003：665.
[2]	Sun Y， Medical Oncology[M]. Beijing: People's medical publishing house， 2003: 665.
[3]	师林，柯斌，李永浩.益气养阴法对晚期肺癌患者化疗后消化道反应及生活质量的影响[J].中国实验方剂学杂志，2012，18（16）：242.
[4]	Shi L， Ke B， Li YH. Effect of supplementing Qi and nourishing Yin on gastrointestinal reactions and quality of life in patients with advanced lung cancer after chemotherapy[J]. Chin J Exp Med Formul， 2012， 18(16):242.
[5]	周清华，孙燕.恶性肿瘤TNM分期[M].7版.天津：天津科技翻译出版公司，2012：140-143.
[6]	Zhou QH， Sun Y. TNM Classification of Malignant Tumours[M]. 7th Edition. Tianjin:Tianjin science and technology translation and publishing company， 2012:140-143.
[7]	曾益新.肿瘤学[M].2版.北京：人民卫生出版社，2004：276-277，287.
[8]	Zeng YX. Oncology[M]. 2th Edition. Beijing: People's medical publishing house， 2004:276-277， 287.
[9]	王卫霞，王谦.人参皂甙的免疫调节作用及其应用[J].中华中医药杂志，2005，20（4）；234-236.
[10]	Wang WX， Wang Q. Immune regulatory action of Ginsenoside and its application[J]. China J Tradit Chin Med Pharm， 2005， 20(4): 234-236.
[11]	周世文，徐传福.多糖的免疫药理作用[J].中国生化药物杂志，1994，15（2）：143.
[12]	Zhou SW， Xu CF. The pharmacological effects of Polysaccharids on immune[J]. Chin J Biologic Pharm， 1994， 15(2):143.
[13]	韩凤梅，刘春霞，陈勇.山麦冬多糖对免疫低下小鼠的保护作用[J].中国医药学报，2004，19（6）：347-348.
[14]	Han FM， Liu CX， Chen Y. Immunoloregulation effect of PoIysaccharides from Radix Liriopes in immunosuppressive mice[J]. Chin J Tradit Chin Med Pharm. 2004， 19(6):347-348.
[15]	袭燕，李岩，梁婧，等.肺癌患者Th1和Th2类细胞因子的基因检测及其与化疗的关系[J].中华肿瘤防治杂志，2006，13（19）：1485.
[16]	Xi Y， Li Y， Liang J， et al. Gene expressions of Th1 and Th2 cytokines in peripheral blood of patients with lung carcinoma and relationship between their expression and chemotherapy[J].Chin J Cancer Prev Treat， 2006， 13(19):1485.
[17]	周岱翰.中医肿瘤学[M].北京：中国中医药出版社，2011：197.
[18]	Zhou DH. TCM Oncology[M]. Beijing: Chinese press of traditional Chinese medicine， 2011:197.
[19]	李和根.刘嘉湘教授以扶正法为主治疗肺癌经验[J].四川中医，2005，23(7):5-6.
[20]	Li HG. Liu Jiaxiang's experience in the treatment of lung cancer by strengthening body resistance[J]. Sichuan J Tradit Chin Med， 2005， 23(7):5-6.